The world’s first needle-free COVID-19 vaccine will be administered in three doses—zero, on the 28th day and the 56th day, though the company is also working on a two-dose regimen.
With an impending third wave, inoculating a majority of the population is critical. Zydus readies to roll out the Covid-19 jab for 12+ kids—a vulnerable and sizeable population—next month.
India’s vaccine giant faces the huge social responsibility of supply into the domestic market and a contractual demand for export of vaccines to foreign countries.
Bharat Biotech, founded by Krishna Ella and his wife Suchitra, has been at the forefront of making vaccines for a while. Yet it took a global pandemic for the spotlight to shine on the company.
The central bank unveils liquidity facility of ₹50,000 crore for access to emergency health services, and ₹10,000 crore for small finance banks’ on-lending, among a slew of measures to fight Covid-19.
As India battles the second wave of Covid-19, which has caused havoc across the country, healthcare companies have come to the fore as lifesavers, to ensure the attack of the virus is countered.
In a big move, India has opened up Covid-19 vaccinations for all adults. However, the country is beset by severe vaccine shortage and other challenges. Will increasing the demand base work?
The country’s daily requirement is over 10 million doses against the production of 2.9 million. The Sputnik V vaccine, which got the nod on Monday, will help bridge the gap, albeit marginally.
One of the issues with vaccine development is the enormous time required to produce one. The Covid-19 vaccine has shown the process can be expedited. But can the process be made even more faster?
Aided by strong demand recovery, credit ratio rebounds to 1.33 in H2FY21, from 0.54 in H1FY21. GDP could grow at 11% in FY22, but the resurgence in Covid-19 cases is a key downside risk, says CRISIL.
